Morgan Stanley Uro Gen Pharma Ltd. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Morgan Stanley holds 2,528,446 shares of URGN stock, worth $61.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,528,446

Previous 2,478,470 2.02%

Holding current value

$61.5 Million

Previous $34 Million 45.35%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$12.96 - $21.42 $647,688 - $1.07 Million	49,976 Added 2.02%	2,528,446 $49.4 Million
Q2 2025 Aug 15, 2025	BUY	$3.9 - $15.46 $6.32 Million - $25.1 Million	1,620,743 Added 188.96%	2,478,470 $34 Million
Q1 2025 May 15, 2025	BUY	$9.27 - $12.13 $838,258 - $1.1 Million	90,427 Added 11.79%	857,727 $9.49 Million
Q4 2024 Feb 14, 2025	SELL	$10.52 - $13.11 $14.9 Million - $18.5 Million	-1,414,164 Reduced 64.83%	767,300 $8.17 Million
Q3 2024 May 14, 2025	BUY	$12.7 - $17.92 $4.35 Million - $6.14 Million	342,758 Added 18.64%	2,181,464 $27.7 Million
Q3 2024 Nov 14, 2024	BUY	$12.7 - $17.92 $4.35 Million - $6.14 Million	342,758 Added 18.64%	2,181,464 $27.7 Million
Q2 2024 May 14, 2025	BUY	$12.72 - $19.2 $13.6 Million - $20.6 Million	1,071,406 Added 139.63%	1,838,706 $30.9 Million
Q2 2024 Oct 17, 2024	BUY	$12.72 - $19.2 $18.4 Million - $27.8 Million	1,448,157 Added 370.8%	1,838,706 $30.9 Million
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $18.4 Million - $27.8 Million	1,448,157 Added 370.8%	1,838,706 $30.9 Million
Q1 2024 Oct 17, 2024	SELL	$13.81 - $19.33 $20 Million - $28 Million	-1,448,157 Reduced 78.76%	390,549 $5.86 Million
Q1 2024 Aug 16, 2024	SELL	$13.81 - $19.33 $891,780 - $1.25 Million	-64,575 Reduced 14.19%	390,549 $5.86 Million
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $891,780 - $1.25 Million	-64,575 Reduced 14.19%	390,549 $5.86 Million
Q4 2023 Aug 16, 2024	SELL	$10.87 - $15.93 $15 Million - $22 Million	-1,383,582 Reduced 75.25%	455,124 $6.83 Million
Q4 2023 Feb 13, 2024	BUY	$10.87 - $15.93 $3.74 Million - $5.48 Million	343,997 Added 309.55%	455,124 $6.83 Million
Q3 2023 Nov 15, 2023	BUY	$8.84 - $22.64 $425,858 - $1.09 Million	48,174 Added 76.52%	111,127 $1.56 Million
Q2 2023 Aug 14, 2023	SELL	$8.75 - $14.29 $704,427 - $1.15 Million	-80,506 Reduced 56.12%	62,953 $651,000
Q1 2023 May 15, 2023	BUY	$7.99 - $11.02 $753,536 - $1.04 Million	94,310 Added 191.89%	143,459 $1.33 Million
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.96 $31,249 - $49,502	4,139 Added 9.2%	49,149 $435,000
Q3 2022 Nov 14, 2022	SELL	$7.21 - $9.41 $275,897 - $360,083	-38,266 Reduced 45.95%	45,010 $376,000
Q2 2022 Oct 27, 2022	BUY	$5.12 - $8.74 $222,120 - $379,167	43,383 Added 108.75%	83,276 $681,000
Q2 2022 Aug 15, 2022	BUY	$5.12 - $8.74 $222,120 - $379,167	43,383 Added 108.75%	83,276 $681,000
Q1 2022 Oct 27, 2022	SELL	$5.92 - $9.73 $256,827 - $422,116	-43,383 Reduced 52.1%	39,893 $349,000
Q1 2022 May 13, 2022	BUY	$5.92 - $9.73 $103,712 - $170,459	17,519 Added 78.3%	39,893 $349,000
Q4 2021 Feb 14, 2022	SELL	$9.03 - $19.13 $192,600 - $408,023	-21,329 Reduced 48.8%	22,374 $214,000
Q3 2021 Nov 15, 2021	BUY	$14.31 - $18.39 $625,389 - $803,698	43,703 New	43,703 $734,000

Others Institutions Holding URGN

# of Institutions

171

Shares Held

43.8M

Call Options Held

1.61M

Put Options Held

433K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $553M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account